Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2007

01-05-2007 | Review

Magnetic resonance imaging of breast lesions—a pathologic correlation

Authors: Gary M. K. Tse, Benjaporn Chaiwun, Ka-Tak Wong, David K. Yeung, Amy L. M. Pang, Alice P. Y. Tang, Humairah S. Cheung

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Login to get access

Abstract

Magnetic resonance imaging of the breast is useful in assessing breast lesions. An understanding of the pathologic characteristics of the tumors may help to understand these magnetic resonance imaging observations.
Large lesional size (>10 mm), ill-defined margin, and irregular outlines are associated with malignancy. These correlate with the pathological features of breast tumor, characterized by rapid growth rate, large size, and infiltrative growth pattern, invasion into stroma resulting in desmoplasia, and hence irregular outline and margin. The detection and estimation of tumor extent of invasive lobular carcinoma is problematic, even with magnetic resonance imaging, which is considered the most sensitivity. This inaccuracy likely derives from the characteristic linear, single cells infiltration growth pattern of the tumor, which is also often underestimated by clinical examination. Estimation of tumor extent after neoadjuvant chemotherapy is also essential but problematic by imaging, as the shrunken tumor becomes fibrotic, with stromal hyalinization, diminished microvasculature and tumor break up causing size underestimation. Non-enhancement of breast tumors occurs in about 8% of cases correlates with diffuse growth pattern, particularly of infiltrative lobular carcinoma. The observation of disproportionately high non-enhancing ductal carcinoma in situ remains an enigma. Finally, early rim enhancement correlates with small cancer nests, low ratio of peripheral to central fibrosis and high ratio of peripheral to central microvessel density. These may be related to increased vascular endothelial growth factor mediated increased microvessel density as well as increased permeability, which manifest as increased rapid contrast uptake and dissipation.
Literature
1.
Heywang SH, Hahn D, Schmidt H et al (1986) MRI imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 10:199–204PubMedCrossRef
2.
Bone B, Pentek Z, Perbeck L et al (1997) Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol 38:489–496PubMed
3.
Stomper PC, Winston JS, Herman S et al (1997) Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 45:39–46PubMedCrossRef
4.
Boetes C, Barentsz JO, Mus RD et al (1994) MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 193:777–781PubMed
5.
Heiberg EV, Perman WH, Herrmann VM et al (1996) Dynamic sequential 3D gadolinium-enhanced MRI of the whole breast. Magn Reson Imaging 14:337–348PubMedCrossRef
6.
Muller-Schimpfle M, Stoll P, Stern W et al (1997) Do mammography, sonography, and MR mammography have a diagnostic benefit compared with mammography and sonography? AJR Am J Roentgenol 168:1323–1329PubMed
7.
Heywang-Kobrunner SH, Viehweg P, Heinig A et al (1997) Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 24:94–108PubMedCrossRef
8.
Morris EA, Schwartz LH, Dershaw DD et al (1997) MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 205:437–440PubMed
9.
Boetes C, Mus RD, Holland R et al (1995) Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197:743–747PubMed
10.
Kepple J, Layeeque R, Klimberg VS et al (2005) Correlation of magnetic resonance imaging and pathologic size of infiltrating lobular carcinoma of the breast. Am J Surg 190:623–627PubMedCrossRef
11.
Rieber A, Merkle E, Bohm W et al (1997) MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma. J Comput Assist Tomogr 21:773–779PubMedCrossRef
12.
Orel SG, Schnall MD, Powell CM et al (1995) Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 196:115–122PubMed
13.
Mumtaz H, Hall-Craggs MA, Davidson T et al (1997) Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 169:417–424PubMed
14.
Fischer U, Kopka L, Grabbe E (1999) Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 213:881–888PubMed
15.
Muuller RD, Barkhausen J, Sauerwein W et al (1998) Assessment of local recurrence after breast-conserving therapy with MRI. J Comput Assist Tomogr 22:408–412PubMedCrossRef
16.
Liberman L, Morris EA, Lee MJ et al (2002) Breast lesions detected on MR imaging: features and positive predictive value. AJR Am J Roentgenol 179:171–178PubMed
17.
Siegmann KC, Muller-Schimpfle M, Schick F et al (2002) MR imaging-detected breast lesions: histopathologic correlation of lesion characteristics and signal intensity data. AJR Am J Roentgenol 178:1403–1409PubMed
18.
Elston C, Ellis IO (2000) Assessment of histological grade. In: Elston CW, Ellis IO (eds), Symmets W (Emeritus Editor) The breast, systemic pathology, Col 13. Churchill Livingston, Edinburgh, pp 365–384
19.
Walker RA, Camplejohn RS (1986) DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. J Pathol 150:37–42PubMedCrossRef
20.
Bouzubar N, Walker KJ, Griffiths K et al (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947PubMed
21.
Fechner RE (1987) Fibroadenoma and related lesions. In: Page DL, Anderson TJ (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 72–85
22.
Tsang WY, Chan JK et al (1996) Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics. Am J Surg Pathol 20:921–943PubMedCrossRef
23.
Tse GM, Ma TK, Chu WC et al (2004) Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. Mod Pathol 17:568–572PubMedCrossRef
24.
Nassar H, Qureshi H, Volkanadsay N et al (2006) Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 30:501–507PubMedCrossRef
25.
Orel SG, Schnall MD, LiVolsi VA et al (1994) Suspicious breast lesions: MR imaging with radiologic–pathologic correlation. Radiology 190:485–493PubMed
26.
Weinreb JC, Newstead G (1995) MR imaging of the breast. Radiology 196:593–610PubMed
27.
Krecke KN, Gisvold JJ (1993) Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 161:957–960PubMed
28.
Davis PL, Staiger MJ, Harris KB et al (1996) Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 37:1–9PubMedCrossRef
29.
Paramagul CP, Helvie MA, Adler DD (1995) Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology 195:231–234PubMed
30.
Butler RS, Venta LA, Wiley EL et al (1999) Sonographic evaluation of infiltrating lobular carcinoma. AJR Am J Roentgenol 172:325–330PubMed
31.
Kepple J, Layeeque R, Klimberg VS et al (2005) Correlation of magnetic resonance imaging and pathologic size of infiltrating lobular carcinoma of the breast. Am J Surg 190:623–627PubMedCrossRef
32.
Boetes C, Veltman J, van Die L et al (2004) The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat 86:31–37PubMedCrossRef
33.
AJCC (2002) Cancer staging handbook, 6th edn. Springer, New York, pp 255–282
34.
Qayyum A, Birdwell RL, Daniel BL et al (2002) MR imaging features of infiltrating lobular carcinoma of the breast: histopathologic correlation. AJR Am J Roentgenol 178:1227–1232PubMed
35.
Page DL, Anderson TJ, Sakamoto G (1987) Infiltrating carcinoma: major histological types. In: Page DL, Anderson TJ (eds) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 193–235
36.
Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1545PubMedCrossRef
37.
Calais G, Berger C, Descamps P et al (1994) Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74:1283–1288PubMedCrossRef
38.
Cocconi G, Di Blasio B, Alberti G et al (1984) Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4:309–313PubMedCrossRef
39.
Segel MC, Paulus DD, Hortobagyi GN (1988) Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169:49–54PubMed
40.
Partridge SC, Gibbs JE, Lu Y et al (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179:1193–1199PubMed
41.
Esserman L, Kaplan E, Partridge S et al (2001) MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8:549–559PubMedCrossRef
42.
Delille JP, Slanetz PJ, Yeh ED et al (2003) Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 228:63–69 (Epub 2003 May 29)PubMedCrossRef
43.
Yeh E, Slanetz P, Kopans DB, Rafferty E et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184:868–877PubMed
44.
Dao TH, Rahmouni A, Campana F (1993) Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 187:751–755PubMed
45.
Wasser K, Sinn HP, Fink C et al (2003) Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13:1213–1223 (Epub 2002 Nov 30)PubMed
46.
Elston CW, Ellis IO, Pinder SE (2000) Effects of treatment. In: Elston CW, Ellis IO (eds), Symmets W (Emeritus Editor) The breast, systemic pathology, Col 13. Churchill Livingston, Edinburgh, pp 463–476
47.
Knopp MV, Brix G, Junkermann HJ et al (1994) MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 2:633–658PubMed
48.
Harms SE, Flamig DP, Hesley KL et al (1993) Fat-suppressed three-dimensional MR imaging of the breast. Radiographics 13:247–267PubMed
49.
Bone B, Aspelin P, Bronge L et al (1996) Sensitivity and specificity of MR mammography with histopathological correlation in 250 breasts. Acta Radiol 37:208–213PubMedCrossRef
50.
Gilles R, Guinebretiere JM, Lucidarme O et al (1994) Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 191:625–631PubMed
51.
Boetes C, Strijk SP, Holland R et al (1997) False-negative MR imaging of malignant breast tumors. Eur Radiol 7:1231–1234PubMedCrossRef
52.
Teifke A, Hlawatsch A, Beier T, Werner Vomweg T, Schadmand S et al (2002) Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T. Radiology 224:881–888PubMedCrossRef
53.
Ghai S, Muradali D, Bukhanov K et al (2005) Nonenhancing breast malignancies on MRI: sonographic and pathologic correlation. AJR Am J Roentgenol 185:481–487PubMed
54.
Hansen S, Grabau DA, Sorensen FB et al (2006) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139–146
55.
Chhieng DC, Tabbara SO, Marley EF et al (2003) Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma. Breast J 9:200–207PubMedCrossRef
56.
Morphopoulos G, Pearson M, Ryder WD et al (1996) Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 180:44–49PubMedCrossRef
57.
Komatsu S, Lee CJ, Hosokawa Y, Ichikawa D et al (2004) Comparison of intraductal spread on dynamic contrast-enhanced MRI with clinicopathologic features in breast cancer. Jpn J Clin Oncol 34:515–518PubMedCrossRef
58.
Ikeda O, Nishimura R, Miyayama H et al (2004) Magnetic resonance evaluation of the presence of an extensive intraductal component in breast cancer. Acta Radiol 45:721–725PubMedCrossRef
59.
Cao Y, Paner GP, Kahn LB et al (2004) Noninvasive carcinoma of the breast: angiogenesis and cell proliferation. Arch Pathol Lab Med 128:893–896PubMed
60.
Ruiz A, Almenar S, Cerda M et al (2002) Ductal carcinoma in situ of the breast: a comparative analysis of histology, nuclear area, ploidy, and neovascularization provides differentiation between low- and high-grade tumors. Breast J 8:139–144PubMedCrossRef
61.
Guidi AJ, Schnitt SJ, Fischer L et al (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80:1945–1953PubMedCrossRef
62.
Weinreb JC, Newstead (1995) G.MR imaging of the breast. Radiology 196:593–610PubMed
63.
Rubens D, Totterman S, Chacko AK et al (1991) Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 157:267–270PubMed
64.
Kerslake RW, Carleton PJ, Fox JN et al (1995) Dynamic gradient-echo and fat-suppressed spin-echo contrast-enhanced MRI of the breast. Clin Radiol 50:440–454PubMedCrossRef
65.
Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMed
66.
Matsubayashi R, Matsuo Y, Edakuni G et al (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841–848PubMed
67.
Ahlgren J, Risberg B, Villman K et al (2002) Angiogenesis in invasive breast carcinoma – a prospective study of tumour heterogeneity. Eur J Cancer 38:64–69PubMedCrossRef
68.
Kato T, Kameoka S, Kimura T et al (2001) Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer. Breast Cancer Res Treat 70:65–74PubMedCrossRef
69.
Santinelli A, Baccarini M, Colanzi P et al (2000) Microvessel quantitation in intraductal and early invasive breast carcinomas. Anal Quant Cytol Histol 22:277–284PubMed
Metadata
Title
Magnetic resonance imaging of breast lesions—a pathologic correlation
Authors
Gary M. K. Tse
Benjaporn Chaiwun
Ka-Tak Wong
David K. Yeung
Amy L. M. Pang
Alice P. Y. Tang
Humairah S. Cheung
Publication date
01-05-2007
Published in
Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9352-3

Other articles of this Issue 1/2007

Breast Cancer Research and Treatment 1/2007 Go to the issue

Epidemology

The effects of radiotherapy for the treatment of contralateral breast cancer

Preclinical Study

Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity

Review Paper

Male breast cancer: a review of clinical management

Epidemiology

Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: case-control study in Korean women and meta-analysis of 12 studies

EPIDEMIOLOGY

Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging

Letter to the editor

Is survivin expression nevertheless related to disease outcome in breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits